Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zanni

Showing results (841-850 of 943) with videos related to

Pageof 95
Sort By:
The Journal of Infectious Diseases|July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender SpectrumLaura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
AIDS (London, England)|June 21, 2024
Association of T-cell subtypes with macrophage-specific arterial infiltration in people with HIVSamuel R Schnittman, Ria Talathi, Moses Q Wilks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
Mechanisms of Ageing and Development|June 13, 2012
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartmentChiara Lobetti-Bodoni, Dario Ferrero, Elisa Genuardi, et al.
The Lancet. Oncology|May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialUmberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
American Journal of Human Genetics|September 27, 2016
TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular AtrophyAntonella Sferra, Gilbert Baillat, Teresa Rizza, et al.
Pageof 95

Showing results (841-850 of 943) with videos related to

Sort By:
Pageof 95
The Journal of Infectious Diseases|July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender SpectrumLaura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
AIDS (London, England)|June 21, 2024
Association of T-cell subtypes with macrophage-specific arterial infiltration in people with HIVSamuel R Schnittman, Ria Talathi, Moses Q Wilks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
Mechanisms of Ageing and Development|June 13, 2012
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartmentChiara Lobetti-Bodoni, Dario Ferrero, Elisa Genuardi, et al.
The Lancet. Oncology|May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialUmberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
American Journal of Human Genetics|September 27, 2016
TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular AtrophyAntonella Sferra, Gilbert Baillat, Teresa Rizza, et al.
Pageof 95